{"schema_version":"1","generated_at":"2026-11-01T12:25:02.012Z","data_as_of":null,"url":"https://www.findmykol.com/kol/anmol-baranwal","json_url":"https://www.findmykol.com/kol/anmol-baranwal/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"anmol-baranwal","name":"Anmol Baranwal","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Lawton","state":"OK","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1083008643","orcid":"0000-0002-3432-0489","openalex":"A5046983933"},"summary":"Anmol Baranwal is an Oncology physician. OpenAlex indexes 72 publications with 336 citations (h-index 11).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":72,"cited_by_count":336,"h_index":11,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":46,"program_years":{"first":2021,"last":null},"rows_total":97,"shown":3,"withheld":94,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":143.09,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1083008643"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":137.67,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1083008643"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":90.04,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1083008643"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1083008643","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Evidence-based risk stratification of myeloid neoplasms harboring <i>TP53</i> mutations","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015238","status":"verified"},{"title":"Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring <i>TP53</i> mutations","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015335","status":"verified"},{"title":"Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01290-0","status":"verified"},{"title":"Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant","year":2025,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.jtct.2025.05.006","status":"verified"},{"title":"Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High‐Risk Myeloid Neoplasms Based on <scp>GvHD</scp> Prophylaxis: <scp>PTCy</scp> Vs. <scp>TAC</scp> / <scp>MTX</scp>","year":2025,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.70059","status":"verified"}],"source":"works"},"contact":{"address_1":"104 NW 31ST ST","city":"Lawton","state":"OK","zip":"735056100","phone":"580-536-2121","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1083008643","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":94,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-06-25","provider_certified":"2025-06-25","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}